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Summary
Fibroblasts often constitute the majority of the stro-
mal cells within a breast carcinoma, yet the functional
contributions of these cells to tumorigenesis are
poorly understood. Using a coimplantation tumor xe-
nograft model, we demonstrate that carcinoma-asso-
ciated fibroblasts (CAFs) extracted from human breast
carcinomas promote the growth of admixed breast car-
cinoma cells significantly more than do normal mam-
mary fibroblasts derived from the same patients. The
CAFs, which exhibit the traits of myofibroblasts, play
a central role in promoting the growth of tumor cells
through their ability to secrete stromal cell-derived
factor 1 (SDF-1); CAFs promote angiogenesis by re-
cruiting endothelial progenitor cells (EPCs) into carci-
nomas, an effect mediated in part by SDF-1. CAF-
secreted SDF-1 also stimulates tumor growth directly,
acting through the cognate receptor, CXCR4, which is
expressed by carcinoma cells. Our findings indicate
that fibroblasts within invasive breast carcinomas
contribute to tumor promotion in large part through
the secretion of SDF-1.*Correspondence: weinberg@wi.mit.eduIntroduction
Neoplastic epithelial cells coexist in carcinomas with
several distinct stromal cell types that together create
the microenvironment of the cancer cells. The contribu-
tion of the stromal microenvironment to the develop-
ment of a wide variety of tumors has been supported by
extensive clinical evidence (Coussens and Werb, 2002;
Jacobs et al., 1999) and by the use of experimental
mouse models of cancer pathogenesis (Barcellos-Hoff
and Ravani, 2000; Bhowmick et al., 2004a; Elenbaas et
al., 2001; Sieweke et al., 1990). The accumulated evi-
dence indicates that tumor cells actively recruit stromal
cells, such as inflammatory cells, vascular cells, and
fibroblasts (Bhowmick et al., 2004b; Cunha et al., 2003;
Olumi et al., 1999; Tlsty, 2001), into the tumor, and that
this recruitment is essential for the generation of a mi-
croenvironment that actively fosters tumor growth.
The presence of large numbers of myofibroblasts,
which express α-smooth muscle actin, is apparent in
the stromal compartment of most invasive human
breast cancers (Sappino et al., 1988). Such myofi-
broblasts, sometimes termed “activated fibroblasts,”
are also known to be present in areas of inflammation
and in tissues undergoing the remodeling seen during
wound healing (Mueller and Fusenig, 2004; Serini and
Gabbiani, 1999). Various types of “reactive” or “des-
moplastic” tumor stroma generate granulation tissue,
which is composed of myofibroblasts as well as large
amounts of accumulated extracellular matrix (Bissell
and Radisky, 2001). Desmoplastic stroma is often found
in commonly occurring epithelial malignancies, includ-
ing those of the breast, prostate, colon, lung, and
uterus (Orimo et al., 2001).
Previous reports indicate poorer prognoses associ-
ated with carcinomas bearing desmoplastic stroma
(Cardone et al., 1997; Maeshima et al., 2002). Stromal
myofibroblasts extracted from human breast carcino-
mas also exhibit distinctive gene-expression profiles
(Allinen et al., 2004), and fibroblasts explanted from hu-
man prostate carcinomas can assist tumor formation
(Olumi et al., 1999). These reports suggest that fibro-
blasts in tumor masses possess biological characteris-
tics distinct from those of normal fibroblasts. However,
the precise functional contributions of the fibroblasts
within stroma to carcinoma growth and progression re-
main poorly understood at the biochemical and cellular
level. In the present study, we sought to elucidate the
properties of fibroblasts isolated from invasive human
mammary carcinomas that facilitate tumorigenesis.
Results
Isolation of Primary Fibroblastic Population
from Invasive Human Breast Cancers
We extracted fibroblasts from six human invasive mam-
mary ductal carcinomas obtained from mastectomies.
The tumor masses were dissociated, and various cell
types were separated to obtain populations of carci-
Cell
336noma-associated fibroblasts (CAFs; see the Supple- f
mmental Experimental Procedures, Isolation of Human
Breast Fibroblasts and Cell Culture, in the Supplemen- n
tal Data available with this article online). We also iso-
lated from each of the same six patients a second pop- l
culation of fibroblasts, taken from a noncancerous
region of the breast at least 2 cm from the outer tumor s
tmargin. We termed these cells “counterpart fibro-
blasts.” All experiments were performed by comparing t
cthese pairs of CAFs and corresponding counterpart fi-
broblasts, thereby avoiding bias due to interindividual c
fdifferences. In addition, we extracted fibroblasts from
a sample obtained from a reduction mammoplasty, in f
iwhich only normal mammary tissue was detectable.
We then verified the purity of the various fibroblast t
ipopulations by immunostaining. These fibroblast pop-
ulations strongly expressed fibroblastic markers such c
das vimentin (Figures 1Aa and 1Ab), prolyl 4-hydroxylase
(Figures 1Ad and 1Ae), fibronectin, and fibroblast sur- b
cface protein (data not shown), whereas these cells were
negative for cytokeratin (Figures 1Ag and 1Ah). We also
ofound that no more than 0.1% of the cells in each fibro-
blast population were positive for CD31, CD45, CD3e, o
bCD11b, CD45R/B220, Ly6G, Ly-6C, and TER-119 using
flow cytometry (data not shown). Taken together, these o
hobservations indicate that these fibroblast populations
were prepared with minimal contamination by epithe- t
blial, endothelial, or hematopoietic cells, such as leuko-
cytes and erythrocytes. e
b
hCAFs Are More Competent in Enhancing
wTumor Growth
eIn order to assess the contribution of various fibroblast
populations to tumor growth in vivo, we developed a
ehuman tumor xenograft model that enabled us to spec-
sify the majority of cells constituting both the stromal
(and epithelial compartments in the engrafted tumors.
wThus, we mixed CAFs, counterpart fibroblasts, or nor-
rmal fibroblasts with MCF-7-ras human breast cancer
tcells in a 3:1 ratio and inoculated these mixtures subcu-
otaneously in immunodeficient nude mice. The MCF-7-
ras cell line carries an activated ras oncogene allele,
allowing these cells to form tumors in the absence of C
Fexogenous estrogen stimulation (Kasid et al., 1985). We
also introduced the GFP reporter gene into these cells E
fto allow their detection in vivo.
In an initial set of experiments, MCF-7-ras cells co- b
tmixed with CAFs (CAF1 cells in Table 1) generated tu-
mors of greater volume (Figure 1Ba) and weight (Figure h
b1Bb) than did MCF-7-ras cells that had been mixed
with other types of fibroblasts prior to injection into p
ihost animals. The tumors that developed in the pres-
ence of CAF1 cells also contained far more GFP- w
ulabeled carcinoma cells when compared to tumors
developing in the absence of CAF1 cells (Figure 1Bc), a
mindicating increased tumor cell proliferation. To further
quantify tumor growth rate, we determined the averaged u
lslope of the tumor growth curves for each tumor type
using mixed effects model estimation (Pinheiro and
dBates, 2000; Supplemental Experimental Procedures,
Data Analysis). This statistical estimation indicated that (
cthe growth rate of tumors (increase of tumor volume/
day) admixed with CAF1 cells increased by 2.8- or 1.6- dold (p = 0.02) when compared to those of tumors co-
ingled with corresponding counterpart fibroblasts or
ormal fibroblasts, respectively (Table 1).
We also confirmed that the initially injected GFP-
abeled MCF-7-ras cells, when comingled with CAF1
ells, contributed prominently to the resulting recon-
tructed tumors by demonstrating strong immunoreac-
ivity against GFP in essentially all cancer cells within
he tumors (Figures 1Ca and 1Cb). This observation ex-
ludes the possibility that contaminating breast cancer
ells, originally present in the tumors from which the
ibroblast populations were prepared, were responsible
or growth of the observed tumors. In addition, the co-
noculated CAF1 cells (Figure 1Cc), as well as the coun-
erpart and normal fibroblasts (data not shown), survived
n large numbers in tumors together with carcinoma
ells for periods of up to 9 weeks after injection, as
etermined by immunohistochemistry using an anti-
ody specific for human vimentin, which MCF-7-ras
ells fail to express.
These initial experiments were extended using pairs
f CAF and counterpart fibroblast populations from five
ther patients, using, as before, admixed normal fibro-
last populations as controls. We observed that four
ut of six CAF populations were more competent in en-
ancing MCF-7-ras tumor growth than were the pa-
ient-specific counterpart fibroblasts, or the normal fi-
roblasts populations (Table 1). These observations
cho findings of others demonstrating that stromal fi-
roblasts isolated from human prostate carcinomas
ave an increased ability to foster tumor formation
hen compared to normal prostatic fibroblasts (Olumi
t al., 1999).
We wished to assess the stability of the tumor-
nhancing phenotype of the CAFs. To do so, we pas-
aged CAF1 cells for up to 10 population doublings
PDs) as pure cultures and then coinjected these cells
ith tumor cells into nude mice. These CAFs largely
etained the tumor-enhancing phenotype, indicating
hat these cells can maintain this trait in the absence
f ongoing contact with carcinoma cells (Figure 1D).
ultured CAFs Express Traits of Activated
ibroblasts (Myofibroblasts)
xpression of α-smooth muscle actin (α-SMA) is a de-
ining characteristic of myofibroblasts (Serini and Gab-
iani, 1999). Using anti-α-SMA antibody, we observed
hat the human mammary carcinomas from which we
ad extracted CAFs carried large numbers of myofi-
roblasts in their stroma (Figure S1). An increased pro-
ortion of α-SMA-positive myofibroblasts also existed
n three isolated CAF populations (Figures 2Ac and 2B)
hen compared to their counterpart fibroblasts (Fig-
res 2Ab and 2B) and to normal fibroblasts (Figures 2Aa
nd 2B). This increased α-SMA expression was largely
aintained in the initially characterized CAF1 cells for
p to nine PDs in vitro (Figure 2B), indicating that iso-
ated CAFs contain a high proportion of myofibroblasts.
Myofibroblasts also exhibit an increased ability to in-
uce collagen gel contraction upon growth in such gels
Hinz et al., 2001). Indeed, we observed that CAF1 cells
ontracted collagen gels to a much greater extent than
id their corresponding counterpart fibroblasts and two
Fibroblast-Secreted SDF-1 Enhances Tumor Growth
337Figure 1. Enhanced Tumor Growth Kinetics of MCF-7-ras Breast Cancer Cells Comingled with CAFs
(A) Fibroblastic properties of extracted primary human fibroblasts. CAFs (b, e, and h); Counterpart fibroblasts (a, d, and g); MCF-7-ras cells
(c, f, and i) Sections were immunostained by anti-vimentin (a, b, and c), anti-prolyl 4-hydroxylase (d, e, and f), or anti-cytokeratin antibodies
(g, h, and i). Scale bar, 50 m.
(B) MCF-7-ras cells were injected alone or coinjected with various fibroblasts subcutanously into nude mice. Tumor volume (a) was ploted in
indicated days. Tumor weight (b) and the number of GFP-labeled MCF-ras cells (c) in each tumor were evaluataed at 62 days after injection.
Error bars depict the standard error around the mean. *p < 0.05 by Student’s t test.
(C) Sections of GFP-labeled MCF-7-ras tumors comingled with CAFs at 60 days after injection were immunostained using an anti-GFP
antibody (b) or stained by hematoxylin and eosin (H&E) (a). A different section (c) from a CAF-containing tumor was also immunostained using
both anti-GFP (pink) and human-specific anti-vimentin (brown) antibodies. Scale bar, 100 m.
(D) MCF-7-ras cells were coinjected with CAF1 (5 or 10 PDs), counterpart (5 PDs), normal fibroblasts (5 PDs), or no fibroblasts subcutaneously
into nude mice. Error bars depict the standard error of the mean.independent normal fibroblasts (Figure 2C). Interest-
ingly, this increased contractile ability was observed
in all six independently isolated CAFs when compared
to corresponding counterpart fibroblasts (data not
shown). CAF1 cells passaged for 10.5 PDs in vitro as
pure cultures also contracted collagen gels to nearly
the same extent as CAF1 cells passaged for five PDs
(Figure 2C). Taken together, these results confirmed
that the CAFs possessed the properties of myofi-
broblasts and maintained these traits without the con-
tinued presence of carcinoma cells. Moreover, we
found a statistically positive correlation (p < 0.001) be-
tween the contractile abilities of the various CAF pop-
ulations and their tumor-enhancing powers (Figure S2;
Supplemental Experimental Procedures, Data Analy-
sis). Hence, CAF populations having greater propor-tions of activated fibroblasts also possess proportion-
ately greater tumor-enhancing ability.
CAFs Enhance Tumor Angiogenesis
Initial cursory examinations of tumor sections contain-
ing various types of admixed fibroblasts suggested that
CAFs show an increased ability to stimulate tumor an-
giogenesis. We assessed formation of tumor-associ-
ated microvasculature at 55–58 days after injection by
examining serial sections from xenograft tumors ad-
mixed with various fibroblasts. Both Masson’s tri-
chrome stain (Figure 3Aa) and anti-CD31 immuno-
staining (Figure 3Ad) revealed extensive vascular
formation in tumors containing CAF1 cells. In contrast,
capillaries in tumors containing counterpart fibroblasts
(Figures 3Ab and 3Ae), normal fibroblasts (Figures 3Ac
Cell
338Table 1. Summary of the Tumor-Promoting Ability in Six Different CAF Populations
CAFs Versus Normal Fibroblasts Versus Counterpart Fibroblasts
Increased
Increased Tumor Increased Increased
Tumor Growth Tumor Tumor
Tumor Weight (g) Weight Tumor Weight (g) Rate Weight Tumor Weight (g) Growth Rate
CAF1 0.384 (n = 10) +++* 0.176 (n = 12) ++* ++* 0.234 (n = 12) +++*
(Std = 0.145) (Std = 0.054) (p = 0.02) (Std = 0.083) (p = 0.02)
(62 days)
CAF2 0.344 (n = 13) ++* 0.207 (n = 12) ++* ++* 0.225 (n = 15) ++*
(Std = 0.105) (Std = 0.076) (p < 0.01) (Std = 0.070) (p < 0.01)
(68 days)
CAF3 0.381 (n = 13) ++* 0.235 (n = 15) +++* +* 0.288 (n = 12) +*
(Std = 0.082) (Std = 0.110) (p < 0.01) (Std = 0.079) (p < 0.01)
(77 days)
CAF4 0.443 (n = 15) − 0.455 (n = 13) − − 0.528 (n = 11) −
(Std = 0.184) (Std = 0.195) (p = 0.7) (Std = 0.188) (p = 0.7)
(98 days)
CAF5 0.337 (n = 11) + 0.306 (n = 14) + − 0.448 (n = 11) −
(Std = 0.144) (Std = 0.112) (p = 0.8) (Std = 0.176) (p = 0.8)
(103 days)
CAF6 0.486 (n = 15) ++* 0.315 (n = 15) ++* + 0.445 (n = 13) +*
(Std = 0.143) (Std = 0.147) (p < 0.01) (Std = 0.136) (p < 0.01)
(83 days)
CAFs and patient-matched, control counterpart fibroblasts were extracted from breast tissues obtained from six human breast cancer
patients. In addition, normal breast fibroblasts were isolated from a healthy patient. Either set of described three types of fibroblasts was
coinjected with MCF-7-ras cells subcutaneously into nude mice. Weight (g) and growth rate (increase of tumor volume/day) of tumors
comingled CAFs were compared to those of tumors containing corresponding counterpart fibroblasts or normal fibroblasts. Thus, relative
increased ratios of the averaged weight and growth rate in tumors containing CAFs are represented using an arbitrary scale. Averaged tumor
weight (g) measured at the indicated day, the standard deviations of the tumor weights, and the numbers of examined tumors are also shown.
*p < 0.05 by Student’s t test for tumor weight and by mixed effects models for tumor growth rate. Arbitrary scale; +++, more than 2-fold up
in CAF-containing tumors; ++,1.5- to w2-fold up; +, 1- to w1.5-fold up; −, not increased; Std, standard deviation.and 3Af), or no fibroblasts (data not shown) were far g
iless developed. Our assessment of the averaged
microvascular density per tumor type indicated a 4.7- S
gfold greater level in CAF-containing tumors (Figure 3Ba)
when compared with tumors containing admixed coun- o
pterpart fibroblasts. Moreover, Chalkley point counting
(numbers of grids covered on each vessel) indicated a E
c7.6-fold greater degree of vascularization in the same
tumors compared to tumors carrying admixed counter- (
part fibroblasts (Figure 3Bb). Taken together, these ob-
servations indicated that in the presence of CAFs, tu- h
amors became more vascularized, suggesting that CAFs
enhance tumor growth, at least in part, by promoting e
ttumor neovascularization.
o
oCAFs Induce Mobilization and Recruitment
hof Endothelial Progenitor Cells
fTumor angiogenesis has previously been demonstrated
ito occur in part through the recruitment of circulating
lEPCs (Bertolini et al., 2003; Lyden et al., 2001). We
ttherefore wished to determine whether the ability of
sCAFs to promote tumor angiogenesis could be attrib-
muted to an increased ability to recruit EPCs into the tu-
Cmor masses. In these experiments, we considered
TSca1+CD31+ cells to represent the EPC-enriched cell
pfraction (Asahara et al., 1997; Rafii and Lyden, 2003);
bthese cells also showed a 20-fold higher ratio of VE-
cadherin-positive cells (an additional specific marker of
fendothelial cell lineages) when compared to Sca1−
CCD31− cells (Figure 3Ca).
We dissociated the whole tumor xenografts into sin- mle-cell suspensions at 60–63 days after subcutaneous
njection and then used flow cytometry to quantify the
ca1+ cell population representing hematopoietic pro-
enitor cells and the Sca1+CD31+ EPC population out
f the total viable cells in tumors. We found a far higher
ercentage of Sca1+ cells (2.9-fold) and Sca1+CD31+
PCs (4.2-fold) in tumors containing CAF1 cells when
ompared to tumors containing counterpart fibroblasts
Figure 3Cb).
Such EPCs likely arrive in tumors via the circulation,
aving been mobilized in the bone marrow and there-
fter introduced into the peripheral circulation (Heissig
t al., 2002). To examine this possibility, we evaluated
he extent of EPC mobilization into the peripheral blood
f mice harboring either CAF1-, counterpart fibroblast-,
r normal fibroblast-containing tumors. We observed a
igher level of Sca1+ (2.1-fold) and Sca1+CD31+ (2.0-
old) mononuclear cells in the circulation of mice bear-
ng CAF1-containing tumors compared to those circu-
ating in mice bearing counterpart fibroblast-containing
umors (Figure 3Cc). Moreover, we failed to observe a
ignificant difference in ratios of circulating EPCs in
ice bearing tumors developing in the absence of
AFs compared to those in non-tumor-bearing mice.
hese observations confirmed that Sca1+CD31+ cell
opulations were indeed mobilized into the circulation
y the CAF-containing MCF-7-ras tumors in vivo.
To address whether these circulating cells could in
act contribute to angiogenesis, we prepared Sca1+
D31+ EPCs or Sca1−CD31− cell fraction from the bone
arrow of RAG-1-deficient mice (having an H2k-b ma-
Fibroblast-Secreted SDF-1 Enhances Tumor Growth
339Figure 2. CAFs Exhibit Characteristics of “Myofibroblasts”
(A) CAF1 cells (c and d), cognate counterpart (b), or normal fibroblasts (a) were cultured in DMEM with 2% FCS. Immunostaining with an anti-
α-SMA antibody (a, b, and c) or control IgG (d). Scale bar, 50 m.
(B) α-SMA-positive cell counts as a fraction of total cell numbers (>100 counted cells) were evaluated in nine independent fields from three
different wells of each fibroblast type under a fluorescence microscope. *p < 0.05.
(C) The area of the contracted gels was measured at the indicated times. The appearance of the contracted gels at 72 hr is also shown.
Error bars depict the standard error of the mean.jor histocompatibility haplotype) by flow cytometry.
Subsequently, we injected 5 × 105 of these bone mar-
row cells intravenously into haplotype mismatched
NOD-SCID (nonobese diabetic, severe combined im-
munodeficient) mice (of an H2k-d haplotype) bearing
20-day-old MCF-7-ras tumors. As shown in Figure 3Cd,
at 21 days after injection of either bone marrow-derived
cell preparation, we found that many tumor-associated
capillaries (revealed by their display of CD31 antigen)
were composed largely of cells staining positively for
the H2k-b haplotype (Figure 3Cd3) by immunofluores-
cence. This demonstrates that circulating Sca1+CD31+
EPCs were, in fact, capable of differentiating into vas-
cular endothelial cells in tumor-associated capillaries.
In contrast, in mice in which control Sca1−CD31− cells
had been injected intravenously, the tumor-associated
vasculature failed to incorporate cells of the H2k-b
haplotype (Figure 3Cd4). These observations indicated
that one of the tumor-enhancing functions of CAFs de-
rives from their ability to mobilize EPCs and to recruit
them into the tumor mass. Once localized within tu-
mors, such EPCs are capable of differentiating into tu-
mor-associated vascular endothelial cells.
CAFs Express High Levels of Stromal Cell-Derived
Factor-1 (SDF-1)
Several secreted factors, such as vascular endothelial
growth factor (VEGF), stromal cell-derived factor-1
(SDF-1), soluble c-Kit ligand, and matrix metalloprotei-
nase 9 (MMP9), have been implicated as possible regu-
lators of EPC proliferation, mobilization, and migration
(Heissig et al., 2002). In order to examine factors in-
volved in the mobilization and recruitment of EPCs, we
performed DNA microarray expression analysis onthree sets of CAFs and the respective patient-specific
counterpart fibroblasts. These analyses showed an ele-
vation of SDF-1 expression in CAFs (data not shown).
We therefore quantified expression levels of both
SDF-1 a and b mRNAs, which are alternative splicing
forms of a common pre-mRNA, in the various stromal
fibroblast populations. Using real time RT-PCR, We
found increased mRNA levels of both SDF-1 a (Figure
4Aa) and b (Figure 4Ab) in CAF1 (2.8- and 5.0-fold,
respectively), CAF2 (2.3- and 2.0-fold), and CAF3 (5.6-
and 2.3-fold) cell populations when compared to the
cognate counterpart fibroblasts of each set of CAFs.
In addition, we performed an ELISA assay on the me-
dium conditioned by each CAF population using an an-
tibody that reacts with both SDF-1 α and β forms. This
assay indicated elevated levels of SDF-1 protein in the
medium conditioned by the CAF1 (1.8-fold), CAF2 (2.6-
fold), and CAF3 (3.1-fold) cells when compared to the
levels produced by the respective counterpart fibro-
blast populations (Figure 4Ac). We failed to observe
higher levels of SDF-1 in CAF4 and CAF5, CAFs that
had previously not shown any tumor-enhancing ability
in vivo (data not shown). Finally, MCF-7-ras cells
showed a far lower level of SDF-1 secretion when com-
pared to CAFs (Figure 4Ac).
We then performed immunostaining using both anti-
SDF-1 and anti-α-SMA antibodies on sections of inva-
sive breast carcinomas obtained from human patients.
We observed that the subset of fibroblast-like cells
positive for α-SMA (as indicated by arrows in Figure
4Bb) also were positive for SDF-1 (as indicated by ar-
rows, Figure 4Ba) in tumor stroma. Notably, the α-SMA
protein present on myofibroblasts in tumor stroma was
largely colocalized with the SDF-1 protein (Figure 4Bf).
Cell
340Figure 3. MCF-7-ras Tumors Developing in the Presence of CAFs are Highly Angiogenic and Recruit Increased Numbers of EPCs
(A) Sections from MCF-7-ras tumors containing various fibroblasts were stained by anti-CD31 antibody (d, e, and f) or by Masson’s trichrome
(a, b, and c). Scale bar, 100 m.
(B) Increased microvascular density (a) and Chalkley counts (b) in tumors comingled with CAFs **p < 0.01. Error bars depict the standard
error of the mean.
(C) (a) Mouse bone marrow cells were stained by anti-Sca1, -CD31, and -VE-cadherin antibodies. (b) MCF-7-ras tumors developing in the
presence of various fibroblasts were dissociated into single cells at 60–63 days after injection. (c) Peripheral blood cells were also harvested
from mice, and the positive cells out of the total viable cells were quantified using anti-Sca1 and anti-CD31 antibodies. *p < 0.05. (d) Frozen
sections were generated from tumors in mice injected intravenously with Sca1+CD31+ EPCs (1, 2, and 3) or control Sca1−CD31− bone marrow
cells (4). The sections were double-immunostained using both anti-H2k-b (1) and anti-CD31 (2) antibodies and double-positive cells are
shown in a merged view (3). Scale bar, 50 m.In contrast, we failed to detect any fibroblast-like cells T
tpositive for SDF-1 in noncancer stroma (as shown by
arrowheads, Figure 4Bc). As previously reported (Pab- s
Slos et al., 1999), we detected the SDF-1 protein to some
extent in normal epithelial cells (as indicated by arrows, C
wFigure 4Bc), breast carcinoma cells (depicted by an ar-
rowhead, Figures 4Bd and 4Bf) and endothelial cells c
s(data not shown). Together, these findings indicate that
the myofibroblasts present within breast carcinomas b
produce higher levels of SDF-1 in vivo than do stromal
fibroblasts present in noncancer stroma. w
c
tSDF-1 Released by CAFs Mediates the Chemotaxis
and Recruitment of EPCs w
pWe wished to test whether SDF-1 released from CAFs
plays a functional role in stimulating EPC recruitment. to this end, we developed an in vitro transwell chemo-
axis assay. GFP-labeled bone marrow fractions were
orted by flow cytometry to enrich for EPCs using anti-
ca1 and anti-CD31 antibodies, as before. Either Sca1+
D31+ EPCs or control Sca−CD31− bone marrow cells
ere then seeded into the upper wells of Boyden
hambers, and the lower wells of these chambers were
eeded with confluent layers of various stromal fibro-
last populations.
GFP-positive cells that migrated into the lower well
ere counted under a microscope 18 hr after initial co-
ulturing. We found a 3.3-fold increase in the chemo-
axis index of the Sca1+CD31+ EPCs when cocultured
ith CAF1 cells in the lower well (Figure 5A) when com-
ared with cognate counterpart fibroblasts. Importantly,
reatment with an anti-SDF-1 neutralizing antibody (10 or
Fibroblast-Secreted SDF-1 Enhances Tumor Growth
341Figure 4. CAFs Produce Increased SDF-1 at Both mRNA and Protein Levels
(A) SDF-1 a (a) and b (b) mRNA levels in various fibroblasts were quantified by real time PCR. SDF-1 protein concentration (c) in the medium
conditioned by these cells was measured by ELISA. Error bars represent the standard errors of the mean in three independent experiments.
*p < 0.05
(B) Invasive human breast carcinoma sections were immunostained with anti-SDF-1 (a, c, d, and f) and anti-α-SMA (b, e, and f) antibodies.
SDF-1+ α-SMA+ myofibroblasts are shown in a merged view (f). Scale bar, 75 m.20 g/ml) inhibited the increased chemotaxis toward
CAFs in a dose-dependent manner, whereas a control
mouse IgG failed to show this effect (Figure 5A). More-
over, chemotaxis toward counterpart or normal fibro-
blasts was not affected by the anti-SDF-1 neutralizing
antibody (Figure 5A). In contrast, the Sca1−CD31− frac-
tion of the bone marrow cells showed a lower degree
of chemotaxis that was largely SDF-1-independent and
unaffected by the type of fibroblasts cultured in the
lower well (Figure 5A). Furthermore, the percentage of
cells expressing CXCR4 —the receptor for SDF-1—was8.6-fold higher in the Sca1+CD31+ fraction when com-
pared to the Sca1−CD31− fraction (Figure 5B), explain-
ing the far higher SDF-1-dependent migration of the
Sca1+CD31+ fraction.
As an additional control, we verified that the migrated
Sca1+CD31+ cells in these chamber assays were in-
deed EPCs by assessing their colony-forming ability
upon long-term culture. After our transwell chemotaxis
migration assay, the mixed cell populations in the lower
wells were cultured in the absence of the upper wells
for an additional 5 weeks. CAF-containing cultures de-
Cell
342veloped EPC colonies (Figure 5Cc) that were double- P
positive for DiI-labeled acetylated-LDL uptake and t
FITC-conjugated Ulex europaeus agglutinin I (lectin) f
binding, both of which are markers of EPCs (Kalka et a
al., 2000). These observations, when taken together, in- i
dicate that CAFs have an enhanced ability in recruiting
EPCs via SDF-1 release in vitro. t
b
6SDF-1 Released by CAFs Contributes
wto the Recruitment of EPCs,
iAngiogenesis, and Tumor Growth
cWe next examined whether SDF-1 released by CAFs
adid indeed play an essential role in enhancing tumor
lgrowth and angiogenesis through EPC recruitment into
Sthe tumors. To do so, we administrated an anti-SDF-1
neutralizing antibody (Coulomb-L’Hermin et al., 1999; tFigure 5. SDF-1 Mediates the Increased Migration of EPC-Enriched Cells toward CAFs
(A) In vitro transwell chemotaxis assays were performed using four to five independent wells of each fibroblast type. The chemotaxis index
was calculated as the ratio of the number of either Scal+CD31+ EPCs or Scal−CD31− cells that migrated toward a particular fibroblast
population to the number of these cells that migrated toward medium-only wells. **p < 0.01. GFP-positive EPCs migrated on CAFs (d),
counterpart (c)-, normal (b)- or nonfibroblast (a) layers. Scale bar, 100 m.
(B) Bone marrow cells were stained with anti-CXCR4, anti-Sca1, and anti-CD31 antibodies. Error bars represent the standard error around
the mean in three independent experiments.
(C) Colonies formed on CAF1 cells were evaluated by FITC-conjugated Ulex europaeus agglutinin I (lectin) binding (a) and DiI-labeled acet-
ylated-LDL uptake (b). Merged images are also shown (c). Scale bar, 50 m.etit et al., 2002) into nude mice bearing MCF-7-ras
umors admixed with either CAF1 cells or counterpart
ibroblasts. Mice received intraperitoneal injections of
ntibodies twice a week for a period of 68 days follow-
ng the initial injection of cells.
Significantly, the resulting MCF-7-ras tumors con-
aining CAFs in mice treated with an anti-SDF-1 anti-
ody showed greatly attenuated tumor growth (Figure
Aa), reduced tumor volume, and decreased tumor
eight (Figure 6Ab) compared to those of CAF-contain-
ng tumors in mice treated with control IgG. The CAF-
ontaining tumors in mice treated with an anti-SDF-1
ntibody also exhibited a 53% reduction in microvascu-
ar density (Figure 6Ac). Moreover, the proportion of
ca1+CD31+ EPCs out of the total viable cells in the
umors was decreased by 36% compared to CAF-con-
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343Figure 6. An Anti-SDF-1 Neutralizing Antibody Attenuated the Increased Growth of MCF-7-ras Tumor Developing in the Presence of CAFs,
Decreased Angiogenesis, and Reduced Recruitment of EPCs into Tumors
(A) Mice bearing MCF-7-ras tumors comixed with CAF1 cells or control counterpart fibroblasts were intraperitoneally treated with either anti-
SDF-1 antibody or control mouse IgG twice a week for a period of 68 days after initial injection of the tumor cells. We examined tumor growth
kinetics (a), tumor weight (b), angiogenesis (c) and the percentage of Sca1+CD31+ EPCs (d) within the tumor masses. *p < 0.05.
(B) (a) Recombinant SDF-1α protein was added to cultured MCF-7-ras cells in the presence of either control IgG or anti-CXCR4 neutralizing
antibody (20 g/ml). Total numbers of MCF-7-ras cells in each of four independent wells were counted at days 3 and 5. (b) Two independent
CXCR4-siRNA or control GFP-siRNA lentivirus vectors were introduced into MCF-7-ras cells. CXCR4 protein expressed on the surface of
MCF-7-ras cells was then analyzed using an anti-CXCR4 antibody by flow cytometry. (c) MCF-7-ras cells expressing various siRNAs or non-
siRNA were cultured in the presence or absence of SDF-1 (100 ng/ml). Total cell numbers in each of four independent wells were counted at
day 5.
Error bars depict the standard error of the mean.taining tumors treated with control IgG (Figure 6Ad),
whereas the anti-SDF-1 antibody failed to affect signifi-
cantly any of the above parameters in those tumors
formed by MCF-7-ras cells to which control counterpart
fibroblasts had been admixed (Figure 6A).
Significantly, as gauged by an ELISA assay, cultured
CAFs secreted SDF-1 at a far higher level (33-fold
greater in the case of CAF1 cells) than did MCF-7-ras
cells, as shown in Figure 4Ac. These findings argue that
the inhibitory effect of the anti-SDF-1 neutralizing anti-
body used in our xenograft model acted largely by in-
hibiting SDF-1 secreted by stromal CAFs, rather than
by inhibiting SDF-1 released by the MCF-7-ras cancer
cells. These observations, together with those de-
scribed earlier, indicate that the SDF-1 released byCAFs in vivo plays a crucial role in enhancing tumor
growth and angiogenesis by recruiting EPCs into tu-
mor masses.
Stromal SDF-1 Enhances Tumor Growth
by Paracrine Stimulation of Tumor Cells
Recent reports have indicated that SDF-1 boosts the
proliferation of several cancer cell lines in culture, in-
cluding breast carcinoma cells (Allinen et al., 2004; Hall
and Korach, 2003). For this reason, we tested whether
CAF-secreted SDF-1 could also directly stimulate MCF-
7-ras cell proliferation. Thus, we first treated MCF-7-
ras cells with recombinant SDF-1 α protein in culture.
Indeed, SDF-1 (applied at 1, 10, or 100 ng/ml) stim-
ulated MCF-7-ras cell proliferation in a dose-dependent
Cell
344Figure 7. Schematic Representation of Tumor-Promoting Effects Provoked by Stromal Fibroblasts within Invasive Human Mammary Carci-
nomas
(A) MCF-7-ras tumor cells expressing either control GFP-siRNA, CXCR4-siRNA-1, or -2 vectors were admixed to SDF-1 α- or control GFP-
expressing normal human breast fibroblasts. These mixtures were then injected subcutaneously into nude mice. In each group, statistically
significant difference of tumor volume is indicated by a bucket line. * p < 0.05. Error bars depict the standard error of the mean.
(B) Two mechanisms by which SDF-1 released by stromal fibroblasts in invasive human mammary carcinomas facilitates tumorigenesis.
Stromal fibroblast-derived SDF-1 enhances tumor growth both by stimulating angiogenesis through recruiting circulating EPCs into the tumor
mass (endocrine effect) and by direct paracrine stimulation of tumor cells through CXCR4 expressed on carcinoma cells (paracrine effect).manner, generating 1.2-, 1.37- or 1.5-fold increases in
Ccell numbers, respectively, when compared to non-
SDF-1-treated MCF-7-ras cells (Figure 6Ba). Moreover, g
(an anti-CXCR4 neutralizing antibody (20 g/ml), which
should block the ability of the CXCR4 receptor to bind b
cits SDF-1 ligand, largely inhibited the SDF-1-induced
proliferation (Figure 6Ba), implicating CXCR4 displayed d
gby the MCF-7-ras cells as the mediator of this prolifera-
tion effect. t
We then determined whether direct paracrine stimu-
lation of tumor cells by stromal SDF-1 occurs in vivo. C
eFurthermore, we sought to confirm that SDF-1 acts
through the CXCR4 on the tumor cells themselves in n
taddition to other CXCR4-expressing cells such as
EPCs. To do so, we constructed MCF-7-ras cells un- h
bable to respond to SDF-1 by introducing lentiviral vec-
tors expressing CXCR4-siRNA into these cells. The re- p
isulting significant inhibition of CXCR4 receptor protein
expression (by 73%–78%) in the MCF-7-ras cells by r
Eeither of two CXCR4-siRNA lentivirus vectors (Figure
6Bb) completely abrogated the ability of SDF-1 to stim- t
Sulate MCF-7-ras cancer cell proliferation (Figure 6Bc).
In contrast, a control GFP-siRNA construct failed to p
chave this effect. Importantly, the loss of CXCR4 did not
affect MCF-7-ras cell proliferation in the absence of a
SDF-1 (Figure 6Bc), indicating that the CXCR4-siRNA
vectors did not retard MCF-7-ras cell proliferation D
through nonspecific effects.
In addition, we generated normal human mammary W
sstromal fibroblasts expressing retroviral SDF-1 α- or
control GFP-expression vectors. SDF-1 α-expressing s
gfibroblasts exhibited an 18-fold higher level of SDF-1
protein, as measured by ELISA, when compared to f
ncontrol GFP-expressing fibroblasts (Figure S3). We ad-
mixed MCF-7-ras cells carrying CXCR4- or GFP-siRNAs c
swith SDF-1 α- or control GFP-expressing fibroblasts
before injecting them subcutaneously into nude mice. eWe found that MCF-7-ras tumors expressing either
XCR4-siRNA vector showed more attenuated tumor
rowth kinetics and significantly reduced tumor volume
p < 0.05) in the presence of SDF-1 α-expressing fibro-
lasts compared to MCF-7-ras tumors expressing a
ontrol GFP-siRNA vector (Figure 7A). This observation
emonstrates that stromal SDF-1 enhances tumor
rowth in vivo in part by direct paracrine stimulation
hrough CXCR4 on MCF-7-ras breast cancer cells.
We also found that MCF-7-ras tumors carrying either
XCR4-siRNA vector admixed with control GFP-
xpressing fibroblasts grew more slowly and had a sig-
ificantly decreased tumor volume (p < 0.05) than did
umors arising from these same carcinoma cells that
ad been commingled with SDF-1 α-expressing fibro-
lasts (Figure 7A). This result shows that stromal SDF-1, as
roposed above, also boosts tumorigenesis by affect-
ng other CXCR4-expressing cells besides the MCF-7-
as tumor cells; these other targets might include the
PCs studied in the earlier experiments. Together,
hese findings strongly suggest that CAF-secreted
DF-1 promotes carcinoma growth in vivo by direct
aracrine stimulation through CXCR4 present on breast
arcinoma cells in addition to its endocrine effects that
llow EPC recruitment into tumors (Figures 7A and 7B).
iscussion
hile the presence of fibroblasts in the stroma of inva-
ive mammary carcinomas is well documented, the
pecific contributions of these fibroblasts to tumor
rowth have been unclear. We have shown here that
ibroblasts present in invasive human mammary carci-
oma masses are biologically very different from their
ounterparts located outside of the tumor masses in
everal important functional respects. (1) Fibroblasts
xtracted from within invasive human breast cancer
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345masses are more competent than their counterparts in
enhancing tumor growth by comingled breast cancer
cells. (2) These fibroblasts exhibit increased α-SMA ex-
pression as well as increased contractility, both indica-
tive of myofibroblasts. (3) When comingled with breast
cancer cells, these fibroblasts give rise to highly vascu-
larized tumors. (4) These fibroblasts produce increased
levels of SDF-1. (5) The SDF-1 released by these fibro-
blasts is responsible for recruiting EPCs into tumor
masses, thereby boosting tumor angiogenesis. In addi-
tion, the SDF-1 produced by these CAFs enhances tu-
mor growth by direct paracrine stimulation via CXCR4
displayed by human breast carcinoma cells.
Significantly, the tumor-enhancing capability of CAFs
is largely maintained, at least during 10 PDs in vitro, in
the absence of continuous interaction with carcinoma
cells. The present experiments do not address how
CAFs acquire these unique phenotypes and how these
cells maintain the myofibroblastic phenotypes. Thus,
during tumor formation, preexisting mammary stromal
fibroblasts or recruited progenitors (Ishii et al., 2003)
may be induced by nearby carcinoma cells to convert
into the myofibroblasts. Alternatively, myofibroblasts or
their progenitors may be recruited from outside of the
tumor mass.
Stromal regions microdissected from human breast
cancers show a high frequency of genetic alterations,
such as loss of heterozygosity (LOH) and somatic mu-
tations (Fukino et al., 2004; Kurose et al., 2002; Moinfar
et al., 2000). These observations raise the possibility
that an accumulation of genetic alterations may con-
tribute to the CAFs’ activated, tumor-enhancing pheno-
types. We note, however, that our CAFs show no detecta-
ble aneuploidy as determined by karyotype analysis, no
anchorage-independent growth in culture, and no tu-
morigenicity in vivo (data not shown). Moreover, some
of our CAFs begin to senesce after 15 PDs in culture.
It is also quite likely that CAFs carry epigenetic alter-
ations, such as the generation of an autocrine TGF-β
loop that can convert normal fibroblasts into myofi-
broblasts (Ronnov-Jessen et al., 1996; Serini and Gab-
biani, 1999). Importantly, CAFs exhibit activated pheno-
types (e.g., increased contractility) very similar to those
of myofibroblasts within wound sites. Such non-carci-
noma-derived myofibroblasts may also have the poten-
tial to aid tumor growth. If such capability is indeed
observed, this would indicate that CAFs, such as those
characterized here, are not unique to the stroma of car-
cinomas and that once myofibroblasts are formed,
such cells may already be fully competent to exert tu-
mor-enhancing effects.
We have demonstrated that SDF-1 secreted from
CAFs recruits EPCs into carcinomas, enhancing angio-
genesis and thus tumor growth. This observation mir-
rors the observation that the tumor stroma resembles
that present in sites of tissue injury (Dvorak, 1986).
Thus, SDF-1 released from injured tissues recruits
EPCs into injured sites, inducing tissue regeneration
(Askari et al., 2003; Ceradini et al., 2004; De Falco et
al., 2004; Schober et al., 2003). Moreover, our finding
that CAFs release higher levels of SDF-1 is supported
by recent work indicating that myofibroblasts extracted
from human mammary tumors express increased levels
of the SDF-1 mRNA (Allinen et al., 2004).Our work takes these other observations still further,
by demonstrating that carcinoma cells can utilize the
normal host stromal response by converting recruited
cells to CAFs, which in turn recruit EPCs into the tumor
via SDF-1 (Figure 7B). While CAFs contribute in a major
way to the recruitment of EPCs, it remains to be seen
whether CAF-derived SDF-1 is also involved in recruit-
ing leukocytes into tumors. Fibroblast-secreted SDF-1,
for example, plays a key role in maintaining chronic in-
flammation by regulating the mobilization, recruitment,
and immigration of leukocytes into inflammatory tis-
sues (Douglas et al., 2002; Suratt et al., 2004). More-
over, chronic inflammation aids carcinoma growth by
generating a tumor-prone microenvironment (Coussens
and Werb, 2002). Furthermore, the recruitment of
CD11b+Gr-1+ leukocytes contributes to tumor angio-
genesis by producing angiogenic factors, such as
MMP9, and by directly differentiating into endothelial
cells (Yang et al., 2004). These lines of evidence support
the possibility that CAF-secreted SDF-1 assists tumor
progression in part through an inflammatory response.
Importantly, endogenous CXCR4 expression on car-
cinoma cells is known to correlate with a poor progno-
sis for several types of carcinomas (Balkwill, 2004;
Staller et al., 2003), although relatively little is known
about the role of its ligand, SDF-1, in primary tumor
growth. It is also known that CXCR4 ectopically ex-
pressed on carcinoma cells enhances primary tumor
growth in a mouse xenograft model (Darash-Yahana et
al., 2004) and that the knockdown of CXCR4 expression
in breast carcinoma cells abrogates the tumor growth
(Lapteva et al., 2005; Smith et al., 2004). Moreover, a
small-molecule inhibitor of CXCR4 reduces primary
brain tumor growth (Rubin et al., 2003). Thus, it is likely
that SDF-1 secreted by stromal myofibroblasts signifi-
cantly affects CXCR4-expressing human breast carci-
nomas through direct paracrine stimulation. Inhibition
of the activated SDF-1/CXCR4 signal pathway in a pri-
mary tumor environment may therefore attenuate carci-
noma growth in breast cancer patients.
Experimental Procedures
Immunostaining of the Human Fibroblasts
and Breast Cancer Tissues
For double immunostaining of vimentin and GFP in paraffin sec-
tions of MCF-7-ras tumors, the DAKO Envision Doublestain System
was used. Primary cultured fibroblasts or frozen sections from hu-
man breast carcinomas were also examined by immunofluores-
cence using the antibodies indicated below.
Antibodies
Primary antibodies used for staining included anti-pan-cytokeratin
(Sigma), human specific anti-vimentin (V9; Novocastra Laborato-
ries, Ltd., United Kingdom), anti-fibronectin (Sigma), anti-prolyl
4-hydroxylase (5B5; Dako, Denmark), anti-fibroblast surface pro-
tein (1B10; Sigma), anti-human CD31 (Dako, Denmark; Santa Cruz,
California), α-SMA (1A4; Dako, Denmark), FITC-conjugated anti-
H2k-b, phycoerythrin (PE)-conjugated anti-CD31 (BD PharMingen),
anti-SDF-1 (K15C), and anti-GFP (Abcam, United Kingdom).
Measurement of Collagen Gel Contraction
by Human Breast Fibroblasts
2 × 105 fibroblasts were suspended in 300 l of collagen lattices
prepared in 24-well plates, and 4–5 independent collagen gels in-
cluding various fibroblasts were cultured in DMEM with 2% FCS.
Cell
346The assay was performed as previously described (Bogatkevich et m
aal., 2001).
Subcutaneous Tumorigenicity Assays F
One million MCF-7-ras cells and three million fibroblasts of various E
types were coinjected subcutaneously into nude mice. Tumorige- C
nicity assays were performed as previously described (Elenbaas et b
al., 2001). w
c
tPlasmid Construction
mThe GFP gene was cloned into the pWZL-Blasticidin retroviral vec-
ator. The human SDF-1 a cDNA (Shirozu et al., 1995) was also cloned
cinto the pBabe-puro retroviral vector. For inhibition of endogenous
oCXCR4 expression in MCF-7-ras cells, oligonucleotides against hu-
Cman CXCR4 or GFP genes were generated and cloned into a lenti-
Mvirus-derived pLKO-puro-RNAi vector (Stewart et al., 2003). The fol-
lowing oligomers were used: CXCR4-siRNA-1, 5#-TGGAGGGGAT
CAGTATATACA-3#; CXCR4-siRNA-2, 5#-GTTTTCACTCCAGCTAAC I
ACA-3# as previously described (Anderson et al., 2003; Doench et 1
al., 2003); GFP-siRNA, 5#-GCAAGCTGACCCTGAAGTTCA-3#. b
S
cRetroviral and Lentiviral Infections
mRetrovirus infection was performed as previously described (Elen-
Dbaas et al., 2001). pBabe-puro-SDF-1 a or -GFP vectors were used
5to infect normal human breast tissue-derived fibroblasts immortal-
eized by hTERT, the catalytic subunit of telomerase. A pWZL-Blas-
tticidin-GFP vector was also introduced by infection into MCF-7-
ras cells. Lentivirus infection of either siRNA-CXCR4 or siRNA-GFP
vector was performed as previously described (Stewart et al., M
2003). After infection, MCF-7-ras cells were selected by 2 g/ml 1
puromycin for 3.5 days and used for experiments on the following t
day. n
a
Real Time PCR c
Quantitative real time RT-PCR analysis was performed as pre- o
viously described (Brisken et al., 2002). Data were normalized rela- r
tive to the expression level of β2-microglobin for each sample. c
Primers used for RT-PCR were human SDF-1 a, 5#-TGAGAGCTC
GCTTTGAGTGA-3# (sense) and 5#-CACCAGGACCTTCTGTGGAT-3# T
(antisense); SDF-1 b, 5#-CTAGTCAAGTGCGTCCACGA-3# (sense) i
and 5#-GGACACACCACAGCACAAAC-3# (antisense); and b2-micro- M
globin, 5#-TGAGTGCTGTCTCCATGTTTGA-3# (sense) and 5#-TCTG f
CTCCCCACCTCTAAGTTG-3# (antisense). 
i
Immunoassay for Human SDF-1 s
1.5 × 106 fibroblasts were cultured in DMEM with 2% FCS on a 10 m
cm culture plate for 2 days. The supernatants were measured using
a commercially available SDF-1 ELISA kit (R&D Systems).
S
Evaluation of Angiogenesis in Xenograft MCF-7-ras Tumors S
Serial sections (taken at 2 mm intervals) were prepared from MCF- m
7-ras tumors (comingled with various fibroblasts or no fibroblasts). h
A total of 30 sections from six independent tumors of each group
were then immunostained using an anti-CD31 antibody. Microves-
sel density was assessed as described previously (Weidner et al., A
1991). After taking these counts, a 49-point Chalkley point eyepiece
graticule (Klarmann Rulings, Inc., New Hampshire) was employed W
over the same tissue section and the number of graticular points r
(at ×400 magnification) that fell within the lumen of vessels was B
counted (Fox et al., 1995). K
o
Colony Formation Assay of Endothelial Progenitor Cells R
After 5 weeks of coculture in DMEM + 2% FCS, uptake of DiI- s
labeled acetylated-LDL and staining of FITC-conjugated Ulex euro- d
paeus agglutinin I (lectin) were examined according to a method i
previously described (Hatzopoulos et al., 1998). H
f
MIncorporation of EPCs into MCF-7-ras Xenograft Tumors
NOD-SCID (H2k-d haplotype+) and RAG-1-deficient mice (H2k-b L
(haplotype+; Jackson Laboratory,) were used. Sca1+CD31+ or
Sca1−CD31− bone marrow fractions from the RAG-1-deficient mice o
Fwere intravenously injected into the NOD-SCID mice bearing MCF-
7-ras tumors. Frozen sections from the resulting tumors were im- cunostained by FITC-conjugated anti-H2k-b and PE-conjugated
nti-CD31 antibodies.
low Cytometry
xtracted human fibroblasts were stained by biotin-conjugated
D45, CD3e, CD11b, CD45R/B220, Ly6G, Ly-6C, and TER-119 anti-
odies (BD PharMingen). Streptavidin (SA)-allophycocyanin (APC)
as then used for detection of biotin-positive cells. 106 mononu-
lear cells from mouse peripheral blood or bone marrow, 106 cul-
ured MCF-7-ras cells, or 106 cells dissociated from xenograft tu-
ors were incubated for 20 min at 4°C with the following
ntibodies: Anti-FITC- or PE-conjugated Sca1, anti-PE- or APC-
onjugated CD31, VE-cadherin, anti-FITC-conjugated mouse CXCR4,
r anti-PE-conjugated human CXCR4 (12G5) (BD PharMingen).
ells incubated with 7-amino-actinomycin D (7-AAD; BD Phar-
ingen) were analyzed using flow cytometry (Becton Dickinson).
n Vitro Transmigration Assay
× 105 fibroblasts were seeded in the lower well of a 24-well cham-
er two days prior to coculture. GFP-labeled Sca1+CD31+ or
ca1−CD31− cell populations were sorted from whole bone marrow
ells from GFP-transgenic mice (Ikawa et al., 1995) using flow cyto-
etry. 4 × 104 of these bone marrow cells were then seeded in
MEM + 2% FCS in the upper well of a transwell chamber with a
m pore size (Costar, Massachusetts). Cells were incubated with
ither anti-SDF-1 neutralizing antibody or control IgG one day prior
o coculture.
CF-7-ras Cell Proliferation Assay in Culture
× 104 MCF-7-ras cells were cultured in DMEM with 2% FCS in
he presence or absence of SDF-1 α (1–100 ng/ml). An anti-CXCR4
eutralizing antibody (12G5; 20 g/ml) or control mouse IgG was
dded 12 hr prior to treatment with SDF-1 α. 4 × 104 MCF-7-ras
ells carrying different siRNAs were also cultured in the presence
r absence of SDF-1 α (100 ng/ml). Total cell numbers of MCF-7-
as cells in each of four independent wells in 24-well plates were
ounted at the indicated days.
reatment with Anti-SDF-1 Neutralizing Antibody (K15C)
n Mice Bearing Tumors
CF-7-ras cells admixed with either CAFs or control counterpart
ibroblasts were injected subcutaneously into nude mice. K15C (32
g/mouse) or control isotype IgG2 (32 g/mouse) antibodies were
ntraperitoneally injected starting one day prior to cell injection and
ubsequently injected twice weekly at the same dose (32 g/
ouse) for a period of 68 days.
upplemental Data
upplemental Data include three figures and Supplemental Experi-
ental Procedures and can be found with this article online at
ttp://www.cell.com/cgi/content/full/121/3/335/DC1/.
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